Test - Ascendis Pharma JP

NEWS RELEASES

November 22, 2022

Ascendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx Conference

November 14, 2022

Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon™ PTH in Adult Patients with Hypoparathyroidism

November 13, 2022

Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years

Preclinical

Phase 1

Phase 2

Phase 3

TransCon hGH

Pediatric growth hormone deficiency2

test

Phase 1

test

Adult growth hormone deficiency

Phase 1

TransCon PTH

Adult hypoparathyroidism

Phase 2

Preclinical

Phase 1

Phase 2

Phase 3

sss

Phase 1

sdsd

sss

Phase 2

sss

sds

Phase 3

You are about to access www.ascendispharma.us, which includes information intended for U.S. residents only. Click below to confirm.

CONFIRM DENY

You are about to access www.ascendispharma.com. Click below if you wish to proceed.

CONFIRM DENY

You are about to leave the Ascendis Pharma website and will continue on an external website. Ascendis Pharma takes no responsibility for the content of such external website

CONFIRM DENY